{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:24:00Z","timestamp":1777407840313,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Multi-center Clinical Research Project of Peking University First Hospital","award":["2022CR67"],"award-info":[{"award-number":["2022CR67"]}]},{"name":"Youth Clinical Research Project of Peking University First Hospital","award":["2023YC04"],"award-info":[{"award-number":["2023YC04"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073935"],"award-info":[{"award-number":["82073935"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274024"],"award-info":[{"award-number":["82274024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40272-024-00665-3","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T07:04:24Z","timestamp":1737183864000},"page":"351-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse Events of Factor Xa Inhibitors in Pediatric Patients: A Meta-analysis and Pharmacovigilance Study"],"prefix":"10.1007","volume":"27","author":[{"given":"Shan","family":"Chong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manqi","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1005","authenticated-orcid":false,"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"4","key":"665_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpeds.2004.06.021","volume":"145","author":"PD Stein","year":"2004","unstructured":"Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr. 2004;145(4):563\u20135.","journal-title":"J Pediatr"},{"key":"665_CR2","doi-asserted-by":"crossref","unstructured":"Lassandro G, Palmieri VV, Palladino V et al. Venous thromboembolism in children: from diagnosis to management. Int J Environ Res Public Health. 2020;17(14).","DOI":"10.3390\/ijerph17144993"},{"issue":"24","key":"665_CR3","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","volume":"128","author":"TM Giglia","year":"2013","unstructured":"Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2013;128(24):2622\u2013703.","journal-title":"Circulation"},{"key":"665_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.855162","volume":"10","author":"N Samji","year":"2022","unstructured":"Samji N, Bhatt MD, Kulkarni K. Challenges in management of VTE in children with cancer: risk factors and treatment options. Front Pediatr. 2022;10: 855162.","journal-title":"Front Pediatr"},{"issue":"3","key":"665_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/MOP.0000000000001128","volume":"34","author":"RR Johnson","year":"2022","unstructured":"Johnson RR, Faustino EVS. Central venous catheter-associated deep vein thrombosis in critically ill pediatric patients: risk factors, prevention, and treatment. Curr Opin Pediatr. 2022;34(3):273\u20138.","journal-title":"Curr Opin Pediatr"},{"key":"665_CR6","doi-asserted-by":"crossref","unstructured":"Young G. New anticoagulants in children. Hematol Am Soc Hematol Educ Prog. 2008;245\u201350.","DOI":"10.1182\/asheducation-2008.1.245"},{"issue":"2 Suppl","key":"665_CR7","doi-asserted-by":"publisher","first-page":"e737S","DOI":"10.1378\/chest.11-2308","volume":"141","author":"P Monagle","year":"2012","unstructured":"Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S-e801S.","journal-title":"Chest"},{"issue":"1","key":"665_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/asheducation-2018.1.399","volume":"2018","author":"P Monagle","year":"2018","unstructured":"Monagle P, Newall F. Management of thrombosis in children and neonates: practical use of anticoagulants in children. Hematol Am Soc Hematol Educ Prog. 2018;2018(1):399\u2013404.","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"1","key":"665_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/ATVBAHA.120.315445","volume":"41","author":"GM Arepally","year":"2021","unstructured":"Arepally GM, Padmanabhan A. Heparin-induced thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(1):141\u201352.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"665_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/MCP.0b013e3283061191","volume":"14","author":"G Le Templier","year":"2008","unstructured":"Le Templier G, Rodger MA. Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med. 2008;14(5):403\u20137.","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"665_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1055\/s-0031-1297173","volume":"37","author":"C Bidlingmaier","year":"2011","unstructured":"Bidlingmaier C, Kenet G, Kurnik K, et al. Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies. Semin Thromb Hemost. 2011;37(7):814\u201325.","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"665_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2018.209528","volume":"104","author":"C Male","year":"2019","unstructured":"Male C, O\u2019Brien SH, Mitchell L. THROMBOTECT takes the lead. Haematologica. 2019;104(4):644\u20135.","journal-title":"Haematologica"},{"issue":"7","key":"665_CR13","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cjca.2022.01.028","volume":"38","author":"JF Heidendael","year":"2022","unstructured":"Heidendael JF, Engele LJ, Bouma BJ, et al. Coagulation and anticoagulation in Fontan patients. Can J Cardiol. 2022;38(7):1024\u201335.","journal-title":"Can J Cardiol"},{"issue":"19","key":"665_CR14","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693\u2013738.","journal-title":"Blood Adv"},{"key":"665_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijcard.2020.11.024","volume":"327","author":"N Kawamatsu","year":"2021","unstructured":"Kawamatsu N, Ishizu T, Machino-Ohtsuka T, et al. Direct oral anticoagulant use and outcomes in adult patients with Fontan circulation: a multicenter retrospective cohort study. Int J Cardiol. 2021;327:74\u20139.","journal-title":"Int J Cardiol"},{"key":"665_CR16","doi-asserted-by":"crossref","unstructured":"Bhat R, Young G, Sharathkumar A. How we treat venous thromboembolism in children in the DOAC era. Blood. 2024;143(5):389\u2013403.","DOI":"10.1182\/blood.2022018966"},{"key":"665_CR17","doi-asserted-by":"crossref","unstructured":"Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020;18(7):1672\u201385.","DOI":"10.1111\/jth.14813"},{"issue":"1","key":"665_CR18","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/S2352-3026(23)00314-9","volume":"11","author":"SH O'Brien","year":"2024","unstructured":"O\u2019Brien SH, Rodriguez V, Lew G, et al. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024;11(1):e27\u201337.","journal-title":"Lancet Haematol"},{"issue":"24","key":"665_CR19","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","volume":"80","author":"MA Portman","year":"2022","unstructured":"Portman MA, Jacobs JP, Newburger JW, et al. Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease. J Am Coll Cardiol. 2022;80(24):2301\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"665_CR20","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","volume":"7","author":"C Male","year":"2020","unstructured":"Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18\u201327.","journal-title":"Lancet Haematol"},{"key":"665_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"665_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"issue":"9","key":"665_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136.","journal-title":"ANZ J Surg"},{"key":"665_CR24","unstructured":"Medicine, U.S.N.L.o. Support materials. 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/manage-recs\/resources. Cited 26 Oct 2023."},{"key":"665_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101795","volume":"55","author":"Z Fu","year":"2023","unstructured":"Fu Z, Liu J, Li S, et al. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. EClinicalMedicine. 2023;55: 101795.","journal-title":"EClinicalMedicine"},{"key":"665_CR26","doi-asserted-by":"crossref","unstructured":"Lensing AWA, Male C, Young G et al. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thromb J. 2018;16:34.","DOI":"10.1186\/s12959-018-0188-y"},{"issue":"22","key":"665_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.021765","volume":"10","author":"BW McCrindle","year":"2021","unstructured":"McCrindle BW, Michelson AD, Van Bergen AH, et al. Thromboprophylaxis for children post-fontan procedure: insights from the UNIVERSE Study. J Am Heart Assoc. 2021;10(22): e021765.","journal-title":"J Am Heart Assoc"},{"key":"665_CR28","unstructured":"Squibb B-M. A study of the safety and effectiveness of apixaban in preventing blood clots in children with leukemia who have a central venous catheter and are treated with asparaginase. 2022. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02369653. Cited 20 Oct 2023."},{"key":"665_CR29","unstructured":"Squibb B-M. A study of the safety and pharmacokinetics of apixaban versus vitamin K antagonist (VKA) or low molecular weight heparin (LMWH) in pediatric subjects with congenital or acquired heart disease requiring anticoagulation. 2022. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02981472. Cited 20 Oct 2023."},{"key":"665_CR30","unstructured":"Daiichi Sankyo I. Hokusai study in pediatric patients with confirmed venous thromboembolism (VTE). 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02798471. Cited 20 Oct 2023."},{"key":"665_CR31","unstructured":"Daiichi Sankyo I. Edoxaban for prevention of blood vessels being blocked by clots (thrombotic events) in children at risk because of cardiac disease. 2022. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03395639. Cited 20 Oct 2023."},{"issue":"10","key":"665_CR32","doi-asserted-by":"publisher","first-page":"e500","DOI":"10.1016\/S2352-3026(19)30161-9","volume":"6","author":"P Monagle","year":"2019","unstructured":"Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019;6(10):e500\u20139.","journal-title":"Lancet Haematol"},{"key":"665_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12959-018-0186-0","volume":"16","author":"D Kubitza","year":"2018","unstructured":"Kubitza D, Willmann S, Becka M, et al. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thromb J. 2018;16:31.","journal-title":"Thromb J"},{"issue":"4","key":"665_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/psp4.12935","volume":"12","author":"SJ Merali","year":"2023","unstructured":"Merali SJ, Byon W, Patel YT, et al. Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder. CPT Pharmacomet Syst Pharmacol. 2023;12(4):500\u201312.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"665_CR35","unstructured":"Daiichi Sankyo I. Phase 1 pediatric pharmacokinetics\/pharmacodynamics (PK\/PD) study. 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02303431. Cited 20 October 2023."},{"key":"665_CR36","unstructured":"FDA. FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots. 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-anticoagulant-blood-thinner-pediatric-patients-treat-potentially-life-threatening. Cited 16 May 2019."},{"key":"665_CR37","unstructured":"FDALabel. Labeling results-Apixaban. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202155s034lbl.pdf. Cited 26 Oct 2023."},{"key":"665_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijcard.2018.06.114","volume":"269","author":"AT Cohen","year":"2018","unstructured":"Cohen AT, Hill NR, Luo X, et al. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants. Int J Cardiol. 2018;269:174\u201381.","journal-title":"Int J Cardiol"},{"key":"665_CR39","unstructured":"FDALabel. Labeling results-Edoxaban. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/206316s019lbl.pdf. Cited 28 Dec 2023."},{"issue":"1","key":"665_CR40","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/hematology.2020000166","volume":"2020","author":"AE Jacobson-Kelly","year":"2023","unstructured":"Jacobson-Kelly AE, Samuelson Bannow BT. Abnormal uterine bleeding in users of rivaroxaban and apixaban. Hematol Am Soc Hematol Educ Prog. 2023;2020(1):538\u201341.","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"665_CR41","unstructured":"FDALabel. Labeling results-Rivaroxaban. 2023. https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/search. Cited 26 Oct 2023."},{"key":"665_CR42","unstructured":"Medicine, N.L.o. Rivaroxaban. 2023. https:\/\/medlineplus.gov\/druginfo\/meds\/a611049.html. 15 Apr 2023."},{"issue":"24","key":"665_CR43","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","volume":"82","author":"RM Payne","year":"2023","unstructured":"Payne RM, Burns KM, Glatz AC, et al. Apixaban for prevention of thromboembolism in pediatric heart disease. J Am Coll Cardiol. 2023;82(24):2296\u2013309.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"665_CR44","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.arth.2020.06.032","volume":"35","author":"AJ Highcock","year":"2020","unstructured":"Highcock AJ, As-Sultany M, Finley R, et al. A prospective cohort comparative study of rivaroxaban, dabigatran, and apixaban oral thromboprophylaxis in 2431 hip and knee arthroplasty patients: primary efficacy outcomes and safety profile. J Arthroplasty. 2020;35(11):3093\u20138.","journal-title":"J Arthroplasty"},{"issue":"3","key":"665_CR45","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1160\/th15-07-0527","volume":"115","author":"SM Kim","year":"2016","unstructured":"Kim SM, Moon YW, Lim SJ, et al. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thromb Haemost. 2016;115(3):600\u20137.","journal-title":"Thromb Haemost"},{"key":"665_CR46","doi-asserted-by":"crossref","unstructured":"Khizroeva J, Makatsariya A, Vorobev A et al. The hemostatic system in newborns and the risk of neonatal thrombosis. Int J Mol Sci. 2023;24(18).","DOI":"10.3390\/ijms241813864"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00665-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:28:16Z","timestamp":1745580496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00665-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00665-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"29 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no financial conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was funded by the National High Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital, 2022CR67; Youth Clinical Research Project of Peking University First Hospital, 2023YC04); the National Natural Science Foundation of China (82073935 and 82274024).The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets are freely and publicly available on the website of US Food and Drug Administration () and ClinicalTrials.gov ().","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Data collection; SC, LS, MQH. Investigation: SC, LS, and GYM. Writing \u2013 original draft: SC, LS, and MQH. Writing \u2013 review and editing: GYM, QX, and YMC. Conceptualization, supervision, and funding acquisition: QX and YMC. All authors have read and agreed to the published version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}